eacs.sanfordguide.comEACS Guidelines 2023 — EACS Guidelines

Site only in current section Advanced Search… Log in Toggle navigation Home Contents Summary of Changes from v.11.1 to v.12.0 Abbreviations Version Information Assessment ART Readiness to Start/Maintain ART Initiation of ART: No Prior ART Exposure Initial Regimens: ART-naïve Adults Primary HIV Infection (PHI) Switch Strategies Virological Failure Pregnancy and HIV ART: TB/HIV Co-infection Post-exposure Prophylaxis (PEP) Pre-exposure Prophylaxis (PrEP) ARV Adverse Effects & Drug Classes DDIs & Prescribing Issues DDIs, Prescribing, Overview Drug-drug interactions ARVs & non-ARVs Analgesics & ARVs Anticoagulants/Antiplatelet Agents & ARVs Antidepressants & ARVs Antihypertensives & ARVs Anti-infective Drugs for OIs and STIs and ARVs Anti-malarial Drugs & ARVs Anti-tuberculosis Drugs & ARVs Anxiolytics & ARVs Bronchodilators & ARVs Contraceptives & ARVs Corticosteroids & ARVs COVID-19 Therapies & ARVs Hormone Replacement Therapy (HRT) & ARVs Immunosuppressants & ARVs Pulmonary Antihypertensives & ARVs Viral Hepatitis Drugs & ARVs Other prescribing issues ARVs: Swallowing Difficulties ARV Dosing: Hepatic Impairment ARV Dosing: Renal Impairment Non-ARV Drug Dosing: Renal Insufficiency Prescribing in Older Persons with HIV Drug Classes To Avoid in Older Persons with HIV Drug Classes to Deprescribe in Older Persons with HIV in Presence of Certain Conditions Hormone Therapy: Gender Transitioning HIV/Hep Co-infection Clinical Management and Treatment of Viral Hepatitis Co-infections Treatment and Monitoring of Persons with HBV/HIV Co-infection HCV/HIV Co-infection Treatment and Monitoring of Persons with HCV/HIV Co-infection HCV Treatment Options DDIs: Viral Hepatitis Drugs & ARVs Tests: Fibrosis / Cirrhosis Hepatitis D and E infection Opportunistic Infections, COVID-19 Overview, When to Start ART Immune Reconstitution Inflammatory Syndrome (IRIS) Primary Prophylaxis of OIs Pneumocystis jirovecii Pneumonia (PcP) Toxoplasma gondii Encephalitis Cryptococcosis Candidiasis Histoplasmosis Talaromycosis Herpes simplex virus (HSV) Varicella zoster virus (VZV) Cytomegalovirus (CMV) Progressive Multifocal Leukoencephalopathy (PML) Bacillary Angiomatosis Cryptosporidiosis Non-Tuberculous Mycobacteria (NTM) Cystoisosporiasis Visceral Leishmaniasis Tuberculosis Management of COVID-19 in persons with HIV Management of Mpox in Persons with HIV Co-morbidities Co-morbidities, Overview Substance Use: Alcohol Opioid Addiction, Pharmacological Treatment Cancer Cancer: Screening Methods Cancer: Treatment Monitoring Lifestyle Interventions Cardiovascular Disease Prevention of Cardiovascular Disease (CVD) Hypertension: Diagnosis, Grading & Management Hypertension: Drug Sequencing Management* DDIs: Anti-hypertensives & ARVs Type 2 Diabetes Dyslipidemia Dyslipidaemia Treatment Goals for LDL-c to Reduce Cardiovascular Risk Depending on CV Risk Estimation* Bone Disease Bone Disease Vitamin D Deficiency Fracture Reduction Kidney disease Kidney Disease: Definition, Diagnosis and Management ARV-associated Nephrotoxicity Proximal Renal Tubulopathy (PRT) ARV dosing: renal impairment Liver Disease Increased ALT/AST: Work-up & Management Liver Cirrhosis: Classification, Surveillance Liver Cirrhosis: Management Non-Alcoholic Fatty Liver Disease (NAFLD) Hepatorenal Syndrome /Acute Kidney Injury (HRS-AKI) ARV Dosing: Hepatic Impairment Lipodystrophy and Obesity: Hyperlactataemia and Lactic Acidosis Travel Travel Antimalarials & ARVs: DDI Vaccination Sexual, Reproductive Health Sexual and Reproductive Health Sexual Dysfunction Treatment of Sexual Dysfunction Mental Health: Depression & Anxiety Disorders Depression: Screening, Diagnosis and Management Antidepressants DDI: Antidepressants and ARVs Anxiety Disorders: Screening and Diagnosis Anxiety Disorders: Management Classification, Doses and Adverse Effects of Anxiolytics and Other Medications used to Treat Anxiety DDI: Anxiolytics & ARVs Cognitive Impairment Use of Patient Reported Outcome Measures (PROMs) in HIV Clinical Care Chronic Lung Disease Chronic Lung Disease DDI: Bronchodilators & ARVs DDI: Pulmonary Antihypertensives & ARVs Managing Older Persons with HIV Frailty Falls Solid Organ Transplant (SOT) Solid Organ Transplantation (SOT) DDI: Immunosuppressants & ARVs Paediatric HIV Treatment ART: Initiation and Initial Regimen ART: Preferred & Alternative First Line Options, Formulations, Dosing Switch Strategies, Special Situations Adherence, Virological Failure and Second Line ART General Principles of Postnatal Prophylaxis and Infant Feeding References References, Overview Assessment of Initial & Subsequent Visits, References ARV Treatment, References DDIs & Other Prescribing Issues, References Co-morbidities Prevention & Management, References Chronic Viral Hepatitis Co-infections, References Opportunistic Infections and COVID-19, References Paediatric HIV Treatment References You are here: Home Toggle navEACS Guidelines 2023 https://eacs.sanfordguide.com https://eacs.sanfordguide.com/@@site-logo/eacs-logo.png EACS Guidelines 2023 Introduction Welcome to the EACS Guidelines 2023! These Guidelines were developed by the European AIDS Clinical Society (EACS), a not-for-profit organisation, whose mission is to promote excellence in standards of care, research and education in HIV infection and related co-infections, and to actively engage in the formulation of public health policy, with the aim of reducing the HIV disease burden across Europe. The EACS Guidelines were first published in 2005, and are currently available, online as a pdf and web-based version, and as a free App for iOS and Android devices. The pdf version continues to be translated into several different languages. The Guidelines undergo formal minor revisions annually and major revisions every second year. Interim updates may however also be provided at any time the panels consider it necessary. The aim of the EACS Guidelines is to provide easily accessible and comprehensive recommendations to clinicians involved in all aspects of care. Unless mentioned otherwise, they always refer to the specific management of people with HIV. The EACS Guidelines cover a relatively large and diverse area geographically, with different national levels of access to care. As a natural consequence, the Guidelines aim to cover a relatively wide range of recommendations as opposed to the often more uniform national guidelines. The 2023 version of the Guidelines includes updates of all existing sections. The most essential changes are listed in the Summary of changes from v11.1 to v12.0 Each respective section of the Guidelines is managed by a panel of experienced European HIV experts, with additional experts in other fields of expertise included where necessary. All recommendations are evidence-based whenever possible and based on expert opinions in the rare instances where adequate evidence is unavailable. The Guidelines do not provide formal grades of evidence, panels make decisions by consensus or by vote when necessary and we do not publish results of the votes or discrepancies if any occur. The EACS Guidelines panels are overseen by a Guidelines Chair who serves a three-year term and is elected from the Governing Board. Each panel is led by a Panel Chair, supported by a Vice-Chair and a Young Scientist. The Co-Chair will take over the role of Chair after the Chair’s term expires. Panel membership is reviewed annually and rotation is overseen by the Panel Leads and Guidelines Chair according to a standard operating procedure. Operational matters of the EACS Guidelines are led by a Coordinator in the Medical Secretariat, supported by the EACS Secretariat. Only the latest and key references used to produce the Guidelines are provided in a separate section, see References . A short summary of the key findings of highlighted references is included. Please reference the EACS Guidelines as follows: EACS Guidelines version 12.0, October 2023. Video links to the EACS online course on Management...